Repistat is a novel molecule that has the potential to decelerate the progression of retinitis pigmentosa, an uncommon genetic condition that can result in complete blindness over time. The discovery stems from an Italian study that made the cover of the Journal of Medicinal Chemistry. The molecule was designed and synthesized by a pharmaceutical chemistry research group at the University of Siena in collaboration with the Department of Pharmacy at the University of Pisa, as well as the CNR Institute of Neuroscience, University College London, and the University of Ferrara for biological testing. The experiments were carried out in vitro and on animal models, with the aim that Repistat will one day serve as the foundation for the development of a novel medicine, possibly an eye drop, capable of delaying the progression of the disease.